☀️     🌓

Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

MeReC Extra 29

The National Prescribing Centre (NPC) has published MeReC Extra 29 (PDF). It covers the cardiovascular risks of rosiglitazone and discusses some recent favourable evidence to support the use of patient decision aids.

The review of rosiglitazone details the latest evidence and advice from the Medicines and Healthcare products Regulatory Agency (MHRA). The continued advice is to review the continued risks and benefits of treatment with rosiglitazone at the patient's next routine appointment.

The discussion of patient decision aids (PDA) covers recent evidence that PDAs may aid adherence to treatment. A Cochrane review also found that knowledge is improved, expectations are more realistic and more people are able to make a decision when PDAs are used. It is also noted the PDAs will be available on the forthcoming NPCi website.

Action: Clinicians will find this MeReC Extra to be useful and informative. It is of the usual high standard expected from the NPC.

Share 'MeReC Extra 29' by emailShare 'MeReC Extra 29' on FacebookShare 'MeReC Extra 29' on TwitterShare 'MeReC Extra 29' on LinkedInShare 'MeReC Extra 29' on reddit


2 Comments to “MeReC Extra 29”

  1. Read all about it

    The UK's National Prescribing Centre (NPC) has published MeReC Extra 30 (PDF). It covers the cardiovascular and gastrointestinal safety of NSAIDs, an update on the cardiovascular (CV) risk of glitazones and the results of the ADVANCE study.

    Trackback by Trusted.MD Network — December 7, 2007 #

  2. [...] The update on the CV risk of glitazones provides additional information that has become available since the publication of MeReC Extra 29. [...]

    Pingback by Prescribing Advice for GPs » MeReC Extra 30 — December 5, 2007 #

Leave a Reply to Trusted.MD Network Cancel reply

Your email address will not be published. Required fields are marked *

Please be aware that you comment is subject to our Privacy Policy.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Prescribing Advice for GPs is powered by ClassicPress.
Connect to our RSS or Atom Feeds.